Mesoglycan in treatment of patients with cerebral ischemia: effects on hemorheologic and hematochemical parameters.
The present study evaluates the hematochemical and hemorheologic effects of mesoglycan, a preparation of natural glycosaminoglycans, administered by the intramuscular route to patients with a recent episode of cerebral ischemia. A total of twenty patients (13 males and 7 females), between the ages of 45 and 75, under observation for a cerebral ischemic episode occurring at least 2 months prior to enrollment, were treated with intramuscular mesoglycan (30 mg, twice daily), for 15 days. Blood samples were taken prior to and at the end of treatment to measure the investigated parameters. Following mesoglycan treatment we observed a statistically significant decrease in fibrinogen plasma concentration, total cholesterol and triglycerides, while HDL cholesterol was found to increase. In addition, erythrocytes filterability improved at the end of treatment. No changes were observed in coagulation parameters such as prothrombin time, partial thromboplastin time, or antithrombin III. The results of the present study demonstrate that a 15-days treatment of intramuscular mesoglycan in patients recovering from a cerebral ischemic episode produces significant changes in fibrinogen and lipid plasma levels with no apparent anticoagulant effect.
Vecchio
F
F
Clinica Delle Malattie Nervose e Mentali, Università Degli Studi di Padova, Italy.
Zanchin
G
G
Maggioni
F
F
Santambrogio
C
C
De Zanche
L
L
D000368:Aged; D002545:Brain Ischemia / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D005260:Female; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D018056:Hemorheology / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged
D006025:Glycosaminoglycans; C040617:mesoglycan